N/A
N=12
Atrial Deganglionation as a Therapy for Cardiac Surgery Patients With Atrial Fibrillation
Atrial Fibrillation
Bottom Line
View on ClinicalTrials.gov: NCT05426759 ↗Enrolled (actual)
12
Serious AEs
8.3%
Results posted
Jul 2024
Primary outcome: Primary: The Number of Patients in Sinus Rhythm at 12 Months. — 12 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pulsed Field Ablation of epicardial Ganglionated Plexi. (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Atrian Medical Ltd.
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Number of Patients in Sinus Rhythm at 12 Months. |
12 | — |
| SECONDARY Extension of AERP |
12 | — |
Summary
A prospective single-arm study of ganglionated plexi ablation in cardiothoracic surgery patients with a history of atrial fibrillation.
Eligibility Criteria
Inclusion Criteria
- Age is between 18 and 70 years.
- Scheduled for open-chest cardiothoracic surgery, for coronary artery bypass grafting and/or aortic valve repair/replacement
- Have a documented medical history of paroxysmal or early-stage persistent atrial fibrillation within the previous 12 months.
- Legally competent and willing to sign the informed consent.
- Life expectancy of at least 2 years.
Exclusion Criteria
- Previous cardiac surgery
- Prior pericardial interventions
- Prior endocardial or epicardial pulmonary vein isolation (PVI), or any other invasive AF therapy
- Previous or existing pericarditis
- Use of amiodarone within the previous 12 months.
- Long-standing persistent atrial fibrillation
- Indication for mitral or tricuspid valve surgery
- Indication for concomitant left atrial appendage (LAA) ligation or excision
- History of previous radiation therapy on the thorax
- History of previous thoracotomy.
- Prior electrical or mechanical isolation of the Left Atrial Appendage (LAA)
- The presence of LAA occlusion devices, coronary stents, prosthetic heart valves, pacemakers or implantable cardioverter defibrillators (ICDs)
- Myocardial infarction within the previous 2 months
- New York Heart Association (NYHA) Class IV heart failure symptoms
- Left Ventricular Ejection Fraction (LVEF) 5.0 cm, measured by transthoracic echocardiography (TTE)
- The presence of left atrial thrombus when examined by transesophageal echocardiography (TEE)
- The presence of atrial fibrillation (AF) attributable to non-cardiovascular causes such as thyroid disease, electrolyte imbalance/dehydration or other reversible causes
- Active infection or sepsis as evidenced by increased white blood cell count, elevated C-reactive protein (CRP) or temperature > 38.5°C
- Known or documented carotid stenosis > 80%
- Stroke or transient ischemic attack within the previous 6 months
- Known or documented epilepsy
- Pregnancy or child-bearing potential without adequate contraception
- Circumstances that prevent follow-ups
- Drug abuse
- Patients cannot be enrolled in another clinical study
Data sourced from ClinicalTrials.gov (NCT05426759). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.